title: The future of insulin therapy for patients with type 2 diabetes mellitus.
abstract: Insulin therapy has been the mainstay of therapy for patients with type 2 diabetes mellitus for the past 90 years. This trend is likely to continue as new formulations are developed to more closely mimic physiologic insulin secretion and to provide patients who have diabetes with more convenient options for integrating this therapy into their lifestyle. The present article reviews how the role of insulin continues to evolve, from its earlier use in the treatment paradigm (even at first diagnosis) to its role in combination therapy with incretin-based therapies, as well as new formulations that provide more-convenient forms of insulin replacement therapy.
authors.affiliation: Albert Einstein College of Medicine in Flushing, New York, NY, USA. jtibaldi@aol.com
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Tibaldi
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000502:physiology; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D054795:Incretins / Q000494:pharmacology; D007328:Insulin / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; C517652:hemoglobin A1c protein, human